Phenomix Sciences and InformedDNA Collaborate to Enhance Genetics-Based Obesity Treatment

Launching at HLTH 2024, the groundbreaking partnership offers payers, health systems, employers, and life science organizations access to personalized obesity care and treatment planning based on a patient’s DNA.

Phenomix Sciences, a biotechnology company specializing in precision medicine for obesity treatment, has announced a new collaboration with InformedDNA, a leader in applied genomics solutions. This partnership aims to advance personalized healthcare by integrating Phenomix’s MyPhenome™ genetic obesity test with InformedDNA’s DNAimpact™ precision health platform.

The MyPhenome test, a simple saliva test, provides insights into the genetic and biological factors contributing to obesity. This information helps healthcare providers tailor treatments, including the use of GLP-1 medications, to the individual patient. Research indicates that treatments customized to a patient's genetic profile through the MyPhenome test are twice as effective as standard, generalized treatments.

Mark Bagnall, CEO of Phenomix Sciences, expressed enthusiasm about the collaboration with InformedDNA, highlighting the potential to expand access to precision medicine. He emphasized that this partnership represents a significant advancement in addressing the complexities of metabolic syndrome and obesity, ultimately improving patient outcomes and making personalized healthcare more accessible.

InformedDNA’s board-certified genetic experts will now use the MyPhenome test to guide patients through the process, from the initial saliva sample collection to interpreting the comprehensive test report. These reports provide personalized insights into the causes of a patient’s obesity, enabling healthcare providers to develop more precise treatment plans. These plans may include lifestyle and dietary interventions, medications, and possibly procedures tailored to the patient's genetic makeup.

Surya Singh, MD, CEO of InformedDNA, remarked on the integration of genomics into everyday healthcare, emphasizing that personalized health solutions driven by genetic profiles are already transforming patient care. The partnership with Phenomix Sciences aligns with InformedDNA’s mission to provide tailored therapeutic options, including GLP-1 medications, to those most likely to benefit based on their genetic and phenotypic profiles. This approach aims to deliver better health outcomes and align with the innovative work being done by Phenomix.

InformedDNA has been at the forefront of applied genomics in the United States, providing telegenetic counseling and developing advanced genetic technology for nearly two decades. Their expertise in genetic solutions aims to optimize clinical decision-making, enhance patient outcomes, and reduce healthcare costs. The DNAimpact™ platform, which combines digital patient engagement with proactive care management, covers critical areas such as oncology, cardiology, metabolic syndromes, and polypharmacy.

Phenomix Sciences focuses on precision obesity biotechnology, aiming to tackle obesity globally using proprietary genetic tests, extensive data sets, and advanced analytics. Their deep understanding of the clinical and molecular aspects of obesity allows them to predict patient responses to weight loss interventions with greater accuracy, reducing the variability in treatment outcomes.

This partnership between Phenomix Sciences and InformedDNA represents a significant step forward in the field of precision medicine, offering personalized obesity care based on genetic insights. It promises to improve patient outcomes by providing tailored treatment plans that consider the unique genetic factors contributing to each individual's obesity. The collaboration highlights the ongoing integration of genomics into healthcare, paving the way for more effective and personalized medical treatments.